In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Betnovate, Celestone, Betaderm, Luxiq, Betamethasone valerate Drug Master File in Korea (Betnovate, Celestone, Betaderm, Luxiq, Betamethasone valerate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Betnovate, Celestone, Betaderm, Luxiq, Betamethasone valerate. The MFDS reviews the Betnovate, Celestone, Betaderm, Luxiq, Betamethasone valerate KDMF as part of the drug registration process and uses the information provided in the Betnovate, Celestone, Betaderm, Luxiq, Betamethasone valerate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Betnovate, Celestone, Betaderm, Luxiq, Betamethasone valerate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Betnovate, Celestone, Betaderm, Luxiq, Betamethasone valerate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Betnovate, Celestone, Betaderm, Luxiq, Betamethasone valerate suppliers with KDMF on PharmaCompass.